Matt Lakelin

Oncology

CAR-TCR 2023 – Matt Lakelin

Innovative, advanced therapies have enormous promise, but also come with a host of logistical problems that innovators underestimate at their own peril.

News

Merck rare tumour drug Ezmekly backed for NHS use

Merck's drug for tumours associated with rare disease neurofibromatosis type 1, Ezmekly, has been cleared for NHS use in children as young as two.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Digital

Discover a new era of healthcare panel engagement: Grounded ...

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.

Editor's Picks